CL2007002323A1 - Forma farmaceutica peroral para la anticoncepcion que contiene dienogest igual o menor aque 2,0 mg y etinilestradiol menor que 0,030 mg, en donde dienogest esta contenido con un tamano de particula promedio de 30 a 270 micrometros. - Google Patents
Forma farmaceutica peroral para la anticoncepcion que contiene dienogest igual o menor aque 2,0 mg y etinilestradiol menor que 0,030 mg, en donde dienogest esta contenido con un tamano de particula promedio de 30 a 270 micrometros.Info
- Publication number
- CL2007002323A1 CL2007002323A1 CL200702323A CL2007002323A CL2007002323A1 CL 2007002323 A1 CL2007002323 A1 CL 2007002323A1 CL 200702323 A CL200702323 A CL 200702323A CL 2007002323 A CL2007002323 A CL 2007002323A CL 2007002323 A1 CL2007002323 A1 CL 2007002323A1
- Authority
- CL
- Chile
- Prior art keywords
- dienogest
- less
- ethylinestradiol
- conception
- micrometers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06016694A EP1886694B1 (de) | 2006-08-10 | 2006-08-10 | Perorale Arzneiform mit Dienogest und Ethinylestradiol zur Kontrazeption |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002323A1 true CL2007002323A1 (es) | 2008-02-15 |
Family
ID=37561777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200702323A CL2007002323A1 (es) | 2006-08-10 | 2007-08-09 | Forma farmaceutica peroral para la anticoncepcion que contiene dienogest igual o menor aque 2,0 mg y etinilestradiol menor que 0,030 mg, en donde dienogest esta contenido con un tamano de particula promedio de 30 a 270 micrometros. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1886694B1 (es) |
AR (1) | AR062323A1 (es) |
AT (1) | ATE432714T1 (es) |
CL (1) | CL2007002323A1 (es) |
CY (1) | CY1110348T1 (es) |
DE (1) | DE502006003892D1 (es) |
DK (1) | DK1886694T3 (es) |
DO (1) | DOP2007000122A (es) |
ES (1) | ES2327665T3 (es) |
HR (1) | HRP20090438T1 (es) |
NO (1) | NO20091057L (es) |
PE (1) | PE20080541A1 (es) |
PL (1) | PL1886694T3 (es) |
PT (1) | PT1886694E (es) |
SI (1) | SI1886694T1 (es) |
TW (1) | TW200817012A (es) |
UY (1) | UY30530A1 (es) |
WO (1) | WO2008017331A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010003711B4 (de) * | 2010-04-08 | 2015-04-09 | Jesalis Pharma Gmbh | Verfahren zur Herstellung kristalliner Wirkstoffpartikel |
CN115487198B (zh) * | 2022-09-20 | 2024-01-02 | 华中药业股份有限公司 | 一种快溶出度的左炔诺孕酮制剂及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1216713A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
DE10218107A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
-
2006
- 2006-08-10 PL PL06016694T patent/PL1886694T3/pl unknown
- 2006-08-10 EP EP06016694A patent/EP1886694B1/de active Active
- 2006-08-10 ES ES06016694T patent/ES2327665T3/es active Active
- 2006-08-10 PT PT06016694T patent/PT1886694E/pt unknown
- 2006-08-10 AT AT06016694T patent/ATE432714T1/de active
- 2006-08-10 DE DE502006003892T patent/DE502006003892D1/de active Active
- 2006-08-10 SI SI200630376T patent/SI1886694T1/sl unknown
- 2006-08-10 DK DK06016694T patent/DK1886694T3/da active
-
2007
- 2007-04-26 WO PCT/EP2007/003662 patent/WO2008017331A2/de active Application Filing
- 2007-07-16 TW TW096125903A patent/TW200817012A/zh unknown
- 2007-08-07 UY UY30530A patent/UY30530A1/es unknown
- 2007-08-09 CL CL200702323A patent/CL2007002323A1/es unknown
- 2007-08-09 DO DO2007000122A patent/DOP2007000122A/es unknown
- 2007-08-09 PE PE2007001064A patent/PE20080541A1/es not_active Application Discontinuation
- 2007-08-10 AR ARP070103547A patent/AR062323A1/es not_active Application Discontinuation
-
2009
- 2009-03-09 NO NO20091057A patent/NO20091057L/no not_active Application Discontinuation
- 2009-08-13 HR HR20090438T patent/HRP20090438T1/xx unknown
- 2009-09-03 CY CY20091100928T patent/CY1110348T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT1886694E (pt) | 2009-08-17 |
CY1110348T1 (el) | 2015-04-29 |
TW200817012A (en) | 2008-04-16 |
SI1886694T1 (sl) | 2009-10-31 |
EP1886694A1 (de) | 2008-02-13 |
PL1886694T3 (pl) | 2009-11-30 |
NO20091057L (no) | 2009-03-09 |
WO2008017331A2 (de) | 2008-02-14 |
DE502006003892D1 (de) | 2009-07-16 |
WO2008017331A3 (de) | 2009-01-08 |
HRP20090438T1 (en) | 2009-09-30 |
AR062323A1 (es) | 2008-10-29 |
DOP2007000122A (es) | 2008-02-15 |
EP1886694B1 (de) | 2009-06-03 |
ATE432714T1 (de) | 2009-06-15 |
UY30530A1 (es) | 2008-03-31 |
ES2327665T3 (es) | 2009-11-02 |
PE20080541A1 (es) | 2008-07-10 |
DK1886694T3 (da) | 2009-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007093642A3 (fr) | Formes pharmaceutiques multimicroparticulaires qui resistent a la decharge immediate du principe actif en presence d'alcool | |
HRP20181819T1 (hr) | Formulacija krutog farmaceutskog oblika doziranja koja sadrži lopinavir | |
CL2007002916A1 (es) | Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras. | |
IL199472A0 (en) | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms, processes for the preparation of the same and uses thereof | |
CL2007003855A1 (es) | Composicion que comprende un vehiculo sustrato y un deposito sobre dicho vehiculo sustrato, donde dicho deposito comprende particulas de un compuesto derivado de pregnano; capsula y tableta que la comprenden; y uso en el tratamiento de enfermedades t | |
BRPI0717916A8 (pt) | forma de dosagem sólida para liberação modificada e método para a liberação modificada de ibuprofeno | |
BRPI0716196A2 (pt) | Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos. | |
EP2024871A4 (en) | SYSTEMS AND METHODS FOR MANAGING THE DEVELOPMENT AND MANUFACTURE OF A MEDICAMENT | |
CL2007003108A1 (es) | Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington, | |
IL179240A (en) | Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody | |
IL187475A (en) | A form of oral administration containing one population of micro-particles to release a variable of at least one active anesthetic and a second population of micro-particles containing at least one depressant and their use | |
BRPI0816465A2 (pt) | Métodos para tratamento ou prevenção de infecções do trato respiratório que compreendem a administração de colecalciferol | |
BR112013009153A2 (pt) | formulação de ligante de fosfato para dosagem única. | |
IL194184A0 (en) | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin | |
AP2009004747A0 (en) | Compounds having a potentiating effect on the activity of ethoionamide and uses thereof | |
CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
WO2009092129A8 (en) | Delayed release pharmaceutical composition of duloxetine | |
CL2007002477A1 (es) | Proceso para preparar comprimidos de dihidrocloruro de pramipexol que comprenden ingredientes de formacion de comprimidos intragranulares, dihidrocloruro de pramipexol, un ligante y agentes de formacion de comprimidos extragranulares, el cual se real | |
ZA200801592B (en) | Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor | |
BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
CL2007003643A1 (es) | Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas. | |
CL2008000454A1 (es) | Un granulo que comprende un nucleo que comprende quetiapina y un agente aglutinante y una capa de recubrimiento que comprende un agente lubricante; procedimiento de preparacion; y composicion farmaceutica. | |
CL2007002323A1 (es) | Forma farmaceutica peroral para la anticoncepcion que contiene dienogest igual o menor aque 2,0 mg y etinilestradiol menor que 0,030 mg, en donde dienogest esta contenido con un tamano de particula promedio de 30 a 270 micrometros. | |
CL2007002111A1 (es) | Procedimiento de fabricacion de la emulsion bituminosa que consiste en usar la emulsion primaria de asfalto la cual sirve para la fabricacion secundaria de asfalto cuyo tamano de particula es superior a 2 micrones y una emulsion final que contiene un | |
BRPI0811629A2 (pt) | Composição farmacêutica que compreende a combinação de um agente anti-inflamatório e um agente anticonvulsivo |